Biosimilars threaten Big Pharma's older biologics

A lineup of blockbuster monoclonal antibodies produced by a group of the world's top biopharma companies are now squarely in the crosshairs of the world's top biosimilar developers. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.